

pharma .be

Belgium:
an innovative pharma valley in Europe

Edition 2019

BELGIUM

AN INNOVATIVE PHARMA VALLEY IN EUROPE¹



in pharmaceutical
R&D investment



in pharmaceutical
export



in clinical trial
applications



in pharmaceutical
R&D employment



in pharmaceutical
and biotech patent
applications




in employment
footprint
(direct, indirect, induced)



in added value
as a % of GDP
(direct, indirect, induced)



in total pharmaceutical
employment



¹ Indicators per inhabitant
except for "added value"

Belgium holds a leading position in the European (bio)pharmaceutical sector. Among all countries of the European Union, Belgium has the highest level of pharmaceutical investments in research and development per inhabitant. Together with the third position in pharmaceutical R&D employment per inhabitant, Belgium is a gem in (bio)pharmaceutical innovation within the European Union.


In this brochure you will discover figures that illustrate the vitality of our sector dedicated to patients in Belgium, Europe and the world.

Catherine Rutten
CEO pharma.be



SHARE OF BELGIUM IN EU

Belgium represents only 2.2% of the population in the EU,
but 12.5% of the R&D investments in pharmaceuticals
(in % in 2017)



R&D



- With a total of **3.6 billion euros in 2018**, (bio)pharmaceutical companies in Belgium invest nearly **10 million euros a day** in research and development.
- In 2018 (bio)pharmaceutical companies employed **5,295 researchers in Belgium**. Our country has the third largest number of researchers employed in the (bio)pharmaceutical sector per inhabitant in the EU.
- In Belgium, employment in (bio)pharmaceutical R&D increased with **23.8 %** in the period 2014-2017. In Europe, this growth was **0.3 %**².
- Belgium ranks 3rd in terms of pharmaceutical and biotech patent applications in the EU (per inhabitant)³. In 2018 **315 patent** applications were filed within these domains in Belgium, an increase of **51.4 %** between 2014 and 2018.
- Huge investments in R&D combined with a high level of expertise put Belgium in **2nd place** in the EU, in terms of clinical trial applications per inhabitant. In 2018 two new clinical trial applications were submitted in Belgium every working day⁴.

² EFPIA annual rapport 2018 (27/06/2019)

³ European Patent Office: pharmaceutical + biotech (Dataset August 9, 2019)

⁴ pharma.be. Belgium, leading the way in Clinical Trials (2019)

BELGIUM IN EUROPE

(per inhabitant)



in pharmaceutical R&D investment



in clinical trial applications



in pharmaceutical R&D employment



in pharmaceutical and biotech patent applications

 **+ 23.8%**

Increase in pharmaceutical R&D employment
2014 → 2017

 **+ 0.3%²**


5,295

researchers employed
in the (bio)pharmaceutical
sector in 2018



RISING SHARE OF BELGIUM

in pharmaceutical R&D investments in EU



315
patents in 2018³

+ 51.4%
2014 → 2018

JOBS



- In Belgium **37,073 people** are employed in the (bio)pharmaceutical sector in 2018⁵.
- In Belgium one job in the (bio)pharmaceutical sector leads to **2.2 additional jobs** in other sectors⁶.
- More than **2.3%** of the jobs in Belgium are related to the activities of (bio)pharmaceutical companies⁷.
- The employees within the Belgian (bio)pharmaceutical sector realize **7.7%** of the total added value created by the (bio)pharmaceutical industry in Europe.⁶

⁵ Pharma figures 2018

⁶ Direct, indirect and induced. PWC, Technical Report June 2019: "The economic and societal footprint of the pharmaceutical industry in Europe"

⁷ The employment footprint refers to the direct, indirect and induced employment impact

(PWC, Technical Report June 2019: "The economic and societal footprint of the pharmaceutical industry in Europe")

BELGIUM IN EUROPE




in employment
footprint
(per inhabitant)⁷



in added value
as a % of GDP
(direct, indirect, induced)



in pharmaceutical
total employment
(per inhabitant)



6th
in the EU

for people employed by
(bio)pharmaceutical companies
(in 2017 in absolute numbers)

	117,013
	98,786
	65,400
	63,250
	42,687
	35,711

In Belgium **1** job in the
(bio)pharmaceutical sector




leads to **2.2** additional jobs
in other sectors⁷



7.7%

of the total added value created by
the (bio)pharmaceutical industry in Europe⁶

EXPORT



- In the EU, Belgium is the 2nd largest exporter in (bio)pharmaceutical goods (per inhabitant). (Bio) pharmaceutical companies located in Belgium account for **12.1%** of the total EU (bio)pharmaceutical exports in 2018⁸.
- Belgium ranks 3rd in export of (bio)pharmaceutical products to the world, which totalled **42.9 billion euros** in 2018. That equals **118 million euros** of (bio)pharmaceutical export a day.
- Belgium's (bio)pharmaceutical companies have a resolutely global outlook. Nearly half (**46.3%**) of all (bio)pharmaceutical exports go to countries outside the EU, primarily the United States, Canada and China. **53.7%** of Belgian (bio)pharmaceutical exports go to other EU countries⁸.
- Belgium was a net exporter of (bio)pharmaceutical products in 2018, achieving a positive pharmaceutical trade balance of **6.8 billion euros**.

⁸ EFPIA annual rapport 2018 (27/06/2019)

BELGIUM IN EUROPE



in pharmaceutical export
(per inhabitant)



IRELAND

1



BELGIUM

2



DENMARK

3



in pharmaceutical export
(in absolute value)



GERMANY

1



IRELAND

2




BELGIUM

3

BELGIAN PHARMACEUTICAL TRADE BALANCE

+ 6.8€ billion
(in 2018)





pharma.be, the General Association of the Innovative Medicines Industry, brings together more than 130 innovative (bio)pharmaceutical companies active in Belgium. These companies focus on research and development of new medicinal products for both human and veterinary use and employ more than 37,000 employees in Belgium.

Partner in health and innovation

As a committed partner of physicians, pharmacists, hospitals, authorities and other health partners, pharma.be's mission is to promote the best healthcare by promoting therapeutic innovation in the field of medicinal products for human use. Its top priority is therefore to allow patients the fastest possible access to the most recent treatments from research and development.

